Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gabriel Steg

Showing results (771-780 of 962) with videos related to

Pageof 97
Sort By:
Circulation. Cardiovascular Interventions|September 17, 2017
White Blood Cell Count and Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention in the Contemporary Era: Insights From the PARIS Study (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients Registry)Binita Shah, Usman Baber, Stuart J Pocock, et al.
American Heart Journal|March 1, 2014
Design and rationale of the TOTAL trial: a randomized trial of routine aspiration ThrOmbecTomy with percutaneous coronary intervention (PCI) versus PCI ALone in patients with ST-elevation myocardial infarction undergoing primary PCISanjit S Jolly, John Cairns, Salim Yusuf, et al.
European Journal of Preventive Cardiology|September 22, 2025
Benefit of Icosapent Ethyl Across Types and Sizes of Myocardial Infarction in REDUCE-ITChen Gurevitz, Deepak L Bhatt, Robert P Giugliano, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|September 22, 2016
Impact of proton pump inhibitors and dual antiplatelet therapy cessation on outcomes following percutaneous coronary intervention: Results From the PARIS RegistryJaya Chandrasekhar, Sameer Bansilal, Usman Baber, et al.
Circulation|October 28, 2021
Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABGSubodh Verma, Deepak L Bhatt, Ph Gabriel Steg, et al.
The Canadian Journal of Cardiology|April 28, 2023
Lipoprotein(a) and the Effect of Alirocumab on Revascularization After Acute Coronary SyndromeP Gabriel Steg, Michael Szarek, Marco Valgimigli, et al.
Circulation|July 22, 2024
Demystifying the Contemporary Role of 12-Month Dual Antiplatelet Therapy After Acute Coronary SyndromeMarco Valgimigli, Antonio Landi, Dominick J Angiolillo, et al.
Nature Reviews. Cardiology|March 31, 2025
Factor XI inhibitors for the prevention and treatment of venous and arterial thromboembolismDavide Capodanno, John H Alexander, M Cecilia Bahit, et al.
Journal of the American College of Cardiology|August 12, 2017
Biomarker-Based Risk Model to Predict Cardiovascular Mortality in Patients With Stable Coronary DiseaseDaniel Lindholm, Johan Lindbäck, Paul W Armstrong, et al.
JAMA Cardiology|June 24, 2026
Dual Antiplatelet Therapy Duration in Patients at High Bleeding Risk: A Systematic Review and Meta-AnalysisAndrea Zito, Antonio Landi, Deepak L Bhatt, et al.
Pageof 97

Showing results (771-780 of 962) with videos related to

Sort By:
Pageof 97
Circulation. Cardiovascular Interventions|September 17, 2017
White Blood Cell Count and Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention in the Contemporary Era: Insights From the PARIS Study (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients Registry)Binita Shah, Usman Baber, Stuart J Pocock, et al.
American Heart Journal|March 1, 2014
Design and rationale of the TOTAL trial: a randomized trial of routine aspiration ThrOmbecTomy with percutaneous coronary intervention (PCI) versus PCI ALone in patients with ST-elevation myocardial infarction undergoing primary PCISanjit S Jolly, John Cairns, Salim Yusuf, et al.
European Journal of Preventive Cardiology|September 22, 2025
Benefit of Icosapent Ethyl Across Types and Sizes of Myocardial Infarction in REDUCE-ITChen Gurevitz, Deepak L Bhatt, Robert P Giugliano, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|September 22, 2016
Impact of proton pump inhibitors and dual antiplatelet therapy cessation on outcomes following percutaneous coronary intervention: Results From the PARIS RegistryJaya Chandrasekhar, Sameer Bansilal, Usman Baber, et al.
Circulation|October 28, 2021
Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABGSubodh Verma, Deepak L Bhatt, Ph Gabriel Steg, et al.
The Canadian Journal of Cardiology|April 28, 2023
Lipoprotein(a) and the Effect of Alirocumab on Revascularization After Acute Coronary SyndromeP Gabriel Steg, Michael Szarek, Marco Valgimigli, et al.
Circulation|July 22, 2024
Demystifying the Contemporary Role of 12-Month Dual Antiplatelet Therapy After Acute Coronary SyndromeMarco Valgimigli, Antonio Landi, Dominick J Angiolillo, et al.
Nature Reviews. Cardiology|March 31, 2025
Factor XI inhibitors for the prevention and treatment of venous and arterial thromboembolismDavide Capodanno, John H Alexander, M Cecilia Bahit, et al.
Journal of the American College of Cardiology|August 12, 2017
Biomarker-Based Risk Model to Predict Cardiovascular Mortality in Patients With Stable Coronary DiseaseDaniel Lindholm, Johan Lindbäck, Paul W Armstrong, et al.
JAMA Cardiology|June 24, 2026
Dual Antiplatelet Therapy Duration in Patients at High Bleeding Risk: A Systematic Review and Meta-AnalysisAndrea Zito, Antonio Landi, Deepak L Bhatt, et al.
Pageof 97